These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10493607)

  • 1. Comparative activities of six different fluoroquinolones against 9,682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance programme. The SENTRY participants group.
    Schmitz FJ; Verhoef J; Fluit AC
    Int J Antimicrob Agents; 1999 Aug; 12(4):311-7. PubMed ID: 10493607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
    Biedenbach DJ; Jones RN; Pfaller MA;
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):245-50. PubMed ID: 11404068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.
    Jones RN; Beach ML; Pfaller MA; Doern GV
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):247-52. PubMed ID: 9884844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network.
    Karlowsky JA; Kelly LJ; Thornsberry C; Jones ME; Evangelista AT; Critchley IA; Sahm DF
    Int J Antimicrob Agents; 2002 Jan; 19(1):21-31. PubMed ID: 11814764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity evaluations of gatifloxacin, a new fluoroquinolone: contemporary pathogen results from a global antimicrobial resistance surveillance program (SENTRY, 1997).
    Jones RN; Croco MA; Pfaller MA; Beach ML; Kugler KC;
    Clin Microbiol Infect; 1999 Sep; 5(9):540-546. PubMed ID: 11851706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
    Jones RN; Pfaller MA
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S16-23. PubMed ID: 10984323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
    Loza E; Cantón R; Pascual A; Tubau F; Morosini MI; Almaraz F; Perea E; Martín R; Jones RN; Baquero F
    Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):404-9. PubMed ID: 14525705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
    Blondeau JM; Laskowski R; Bjarnason J; Stewart C
    Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
    Jones RN; Pfaller MA;
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000).
    Gordon KA; Pfaller MA; Jones RN;
    J Antimicrob Chemother; 2002 May; 49(5):851-5. PubMed ID: 12003983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).
    Bell JM; Turnidge JD; Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):315-8. PubMed ID: 12151193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999).
    Gales A; Sader H; Jones RN;
    Antimicrob Agents Chemother; 2001 May; 45(5):1463-6. PubMed ID: 11302811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
    Oliveira AD; D'Azevedo PA; Francisco W
    Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.
    Sahm DF; Critchley IA; Kelly LJ; Karlowsky JA; Mayfield DC; Thornsberry C; Mauriz YR; Kahn J
    Antimicrob Agents Chemother; 2001 Jan; 45(1):267-74. PubMed ID: 11120976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
    Pontani D; Washton H; Bouchillon S; Johnson J
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods.
    Biedenbach DJ; Croco MA; Barrett TJ; Jones RN
    Eur J Clin Microbiol Infect Dis; 1999 Jun; 18(6):428-31. PubMed ID: 10442421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.